Document is current
Any future updates will be listed below
-
Authors
Mounie, Michael https://orcid.org/0000-0003-0298-267X
Dumas, Pierre-Yves
Liva-Yonnet, Sandra
Fabre, Didier
Leguay, Thibault
Galtier, Jean
Berard, Emilie
Hanta, Ramaroson
Gilleron, Véronique
Bertoli, Sarah https://orcid.org/0000-0003-1084-2781
Pigneux, Arnaud
Récher, Christian
Costa, Nadège
- License Information
-
More Information
Article History
Received: 17 April 2023
Revised: 5 June 2023
Accepted: 14 June 2023
First Online: 28 June 2023
Competing interests
: CR: report grants, personal fees, and non-financial support from Abbvie; grants from Amgen; grants, personal fees, and non-financial support from Astellas; grants, personal fees, and non-financial support from BMS; grants, personal fees, and non-financial support from Jazz Pharmaceuticals; grants from Iqvia; personal fees and non-financial support from Novartis; grants from MaatPharma; personal fees and non-financial support from Servier; and personal fees from Takeda. P-YD: Daiichi-Sankyo, Jazz Pharmaceutical, Astellas, Abbvie, Celgene, and Janssen. Sarah Bertoli: Jazz Pharmaceuticals, Daiichi-Sankyo, Sanofi, Astellas, BMS, Abbvie, and Pfizer. Arnaud Pigneux: Grant/Research Support: Astellas and Roches; Speaker’s Bureau: AbbVie, Astellas, Gilead, Pfizer, Roche, and Sanofi; Consultant: AbbVie, Agios, BMS, Gilead, Jazz Pharma, Novartis, Pfizer, Roche, and Takeda.
